Abstract: Objective To analyze the clinical efficacy and safety of endoscopic variceal ligation （EVL） combined with somatostatin in treatment of patients with liver cirrhosis complicated by esophageal variceal bleeding （EVB）. Methods 64 patients with liver cirrhosis complicated by EVB were recruited in our hospital between April 2015 and May 2017,and were divided into two groups receiving somatostatin or somatostatin and EVL. Results At the end of one week treatment,the hemostasis in combination group was 100.0%,significantly higher than 90.6% （P<0.05） in the somatostatin-treated patients,and three patients died in the latter;after treatment,the hepatic nenous pressure gradient （HVPG） in combination group was （6.5±1.0） mmHg,much lower than （11.9±1.1）mmHg in the control,while RBC was （4.7±0.5）×10¹²/L,Hb was（118.5±23.1） g/L,significantly higher than （4.1±0.4）×10¹²/L and（104.4±22.5） g/L in the control（P<0.05）;the hemostasis time was（1.3±0.4） d,blood transfusion was （1.7±1.0）U,and hospital stay was（20.4±3.5） d,significantly shorter or less than （2.8±0.5） d,（2.8±1.5） U and （29.8±4.0） d in the control （P<0.05）;at the end of one-year follow-up,the incidences of rebleeding in the two groups were 53.1% and 86.2% （P<0.05）. Conclusion The emergent application of somatostatin and EVL in dealing with patients with liver cirrhosis complicated by EVB is efficient and safe, which can effectively achieve rapid hemostasis and shorten the hospitalization time.

Key words: Liver cirrhosis, Esophageal variceal bleeding, Endoscopic variceal ligation, Somatostatin, Therapy